Quality and labeling information of *Moringa oleifera* products marketed for HIV-infected people in Zimbabwe

Tsitsi Grace Monera-Penduka,1 Zvijinji Tella Jani,1 Charles Chiedza Maponga,1,2 Josephine Mudzengi,3 Gene D. Morse,2 Charles Fungai Brian Nhachi3

1School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; 2Pharmacy Practice, State University of New York at Buffalo, NY, USA; 3Department of Clinical Pharmacology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

Abstract

Labeling information and quality of marketed *Moringa oleifera* products were assessed. Personnel in 60 pharmacies and 11 herbal shops were interviewed about the sources, dosages, indications and counseling information of *Moringa oleifera* products. Content analysis of written information provided on *Moringa oleifera* products was also done. Three samples of *Moringa* from popular sources were acquired to determine heavy metal content and microbial contamination. The results were compared to specified limits in the European and Chinese pharmacopoeias, World Health Organization guidelines and Bureau of Indian Standards. *Moringa* was available as capsules or powder in 73% of the premises. *Moringa* was recommended for seven different disease conditions. Four different dosage regimens were prescribed. The main references cited for the counseling information were unscientific literature (62%). The selected *Moringa* samples were contaminated with bacteria and fungi above the European Pharmacopoeia specified limits. *Escherichia coli* and *Salmonella* species were present in all three samples. All three samples contained arsenic, nickel and cadmium above the permissible limits. *Moringa oleifera* with variable labeling information and poor microbial and heavy metal quality is widely available in Zimbabwe.

Introduction

When herbal medicines are unregulated, consumers are potentially exposed to unsafe products. Safety issues may arise from circulation of inconsistent or unsubstantiated drug information, heavy metal residues, microbial contamination or adulteration.1,2 Heavy metal and microbial contamination is particularly of concern with HIV-infected individuals. Heavy metals could exacerbate the risk of liver and kidney damage associated with HIV-infection and treatment, while the microbial contamination may increase the risk of opportunistic infections due to a compromised immune system of HIV-infected people.3

In Zimbabwe, like many developing countries, regulation of the sale of herbal medicines is still in its infancy. The relevant statutory instrument was only gazette in September 2015. In addition, the national drug regulatory authority granted a transition period of one year before it would fully enforce the regulations. As a result, the impact of regulation is yet to be realized and unsafe herbal products may still be on the market. Very few studies have been conducted to assess potential safety issues with herbal products available on the market in Zimbabwe.

Assessing potential safety issues of commonly marketed herbal products would provide data to enable risk profiling of the herbs. The data would assist the drug regulatory agency when assessing herbal products for approval, to focus any analysis on relevant safety issues. The data would also serve clinicians as they counsel patients on herbal medicine use.

*Moringa oleifera* (drumstick/horseradish tree/moringa) is a herb commonly used as a nutritional supplement and immune enhancer by HIV-infected people in Zimbabwe. It is rich in nutrients including beta carotene, ascorbic acid, calcium, iron, proteins and carbohydrates and purported to have hypoglycaemic, hypotensive, hypcholesterolemic, anti-ulcer, antibacterial and anti-inflammatory activity.3,5 While there is some evidence to support the health benefits of *Moringa*, very little is known about the safety of marketed *Moringa* products. This study was therefore undertaken to assess the labeling information as well as the heavy metal and microbial content of *Moringa oleifera* products in Zimbabwe.

Materials and Methods

Study design and ethical considerations

The study was a cross-sectional observational study incorporating laboratory assessments. The research protocol was reviewed and approved by the Joint Parirenyatwa Hospital and College of Health Sciences Research Ethics Committee (Harare, Zimbabwe). Oral and written informed consent was obtained from supervising personnel at each of the premises after assurance of confidentiality.

Sampling

A convenience sample of 60 pharmacies and 11 herbal shops was selected. Three sam-
amples of *Moringa* were purchased for determination of microbial and heavy metal contamination. One sample was from a pharmacy, another from a herbal shop and the third from an open market in Harare. Selection was based on the premises that had the highest reported monthly *Moringa* sales.

Assessment of herbal medicine information

Personnel were interviewed about the sources, dosage regimen, indications and counseling information of *Moringa oleifera* using a previously piloted interview script. Labels and available package inserts from *Moringa* products stocked in the premises were reviewed and data on indications, dosage regimen and cautionary messages were captured.

Determination of microbial contamination

The examination of microbial contamination was performed according to the harmonized microbial enumeration tests in the European Pharmacopeia. Enumeration of bacteria was carried out on tryptone soya agar, while that of fungi was done on sabouraud dextrose agar. All samples were diluted with buffered sodium chloride-peptone-water, pH 7.0 to the concentration of 10⁻⁵. Subsequently, 1ml of each dilution was added to two sterile petri dishes of 10 cm diameter. For bacteria, tryptone soya agar was promptly added into each dish, mixed and the agar was allowed to set. After setting of the agar, the plates were incubated (Jeio Tech™ incubator; Jeio Tech Co., Ltd., Daejeon, Korea) at 30-35°C for three days. For fungi, Sabouraud dextrose agar medium was added to each dish, mixed and the content allowed to solidify. The plates were then incubated at 20-25°C for five days. The number of colonies for both bacteria and fungi was counted using a TRINITY V3™ automated zone reader and colony counter (Giles Scientific Inc., Santa Barbara, CA, USA). All tests were carried out in duplicate. A negative control was performed for all tests with sterile peptone water pH 7.0 used in place of the test preparation to verify testing conditions.

Determination of specific microorganisms

To determine contamination with enterobacteria in each sample, 10 g of the sample (weighed using Mettler PM 600 top loading balance) were added to 90 mL of Tryptone soya broth and mixed. After mixing, the material was incubated at 20-25°C for 2 hours. Nine mL of enterobacteria enrichment broth-Mossel were inoculated with 1 mL quantities of the product to be examined. The four resultant dilutions of the preparation which contained 0.1 g, 0.01 g, 0.001 g and 0.0001 g of the product were incubated at 30-35°C for 24 hours. Each of the cultures was sub-cultured on a plate of violet red bile glucose agar and incubated at 30-35°C for 24 hours. Growth of colonies was examined. The smallest quantity of product that gave a positive result and the largest quantity that gave a negative result were noted. These results were used to determine the probable number of bacteria.

To determine contamination with *Escherichia coli*, 10 g of each sample was added to 90 mL buffered peptone water. Ten mL of the preparation was used to inoculate 90 mL of Tryptone soya broth, mixed and incubated at 30-35°C for 24 hours. The container with the material was shaken and 1 mL of tryptone soya broth was transferred to 100 mL of MacConkey broth and incubated at 42-44°C for 24 hours. The preparation was subcultured on a plate of MacConkey agar at 30-35°C for 24 hours. Growth of colonies was examined. To determine contamination with *Salmonella*, 25 g of each sample was added to 225 mL of buffered peptone medium, mixed and incubated at 30-35°C for 24 hours. After incubation, 0.1 mL of buffered peptone water was transferred to 10 mL of Rappaport Vassiliadis *Salmonella* enrichment broth and incubated at 30-35°C for 24 hours. The material was subcultured on plates of xylose, lysine and deoxycholate agar. This was incubated at 30-35°C for 24 hours. Growth of bacteria was examined.

Determination of heavy metal contamination

Herbal medicine samples were digested through wet digestion. For all the samples, 5 g of the powdered sample was placed in a flask. Twenty mL of concentrated HNO₃ 60% was added and heated on hot plate until product stopped producing brown fumes. Thirty mL of 1:1 solution of HNO₃ and perchloric acid 70% were added and heated until a suspension of approximately 1 mL was left in the flask. The residue was cooled and 5 mL of 0.5M HCL was added. Material was diluted with distilled water up to 25 mL and filtered through Whatman filter paper no. 42. The sample was then analyzed using the atomic absorption spectrometer (AAS) for chromium, cadmium, copper, lead, nickel, arsenic and zinc. The results were expressed in parts per million (ppm). The AAS operating parameters used were as shown below in Table 1.

Statistical analysis

The data were analyzed qualitatively and quantitatively using Stata®11.

Results

Source of *Moringa oleifera* products

*Moringa oleifera* was sold in 73% of the premises. The *Moringa* was supplied by local farmers in 94% of the cases. One local open market were the farmers operate from was commonly cited by participants (90%). A small proportion of the proprietors (4%) sold their own cultivated supplies. Occasionally (10%) *Moringa* was imported, mainly from a single South African phyto-pharmaceutical company.

Labeling information available with *Moringa oleifera* products sold in Zimbabwe

*Moringa* was recommended for seven different disease conditions including HIV infection, diabetes, hypertension, joint pain, prostate disorders, tuberculosis and arthritis. Four different dosage regimens were prescribed. The regimen prescribed did not vary with the conditions indicated and did not include the course duration. The main refer-
ences cited for the counseling information were unscientific literature that included books, magazines and newspapers (Table 2).

Microbial counts of *Moringa* samples

All three samples were contaminated with aerobic bacteria and fungi above the European Pharmacopeia limits. *Moringa* from the herbal shop had the highest bacterial count while that from the pharmacy had the highest fungal count. The results are shown below in Table 3.

Presence of *Salmonella species, Escherichia coli* and enterobacteria

All three samples were contaminated with both *Salmonella* species and *Escherichia coli*. None of the samples were contaminated with bile tolerant gram-negative enterobacteria.

| Element | Cr | Cd | Cu | Ni | Pb | Zn | Ar |
|---------|----|----|----|----|----|----|----|
| Wavelength (nm) | 357.9 | 228.8 | 324.8 | 232 | 217.3 | 213.9 | 193.7 |
| Slit width (nm) | 0.2 | 0.5 | 0.5 | 0.2 | 1 | 1 | 1 |
| Lamp current (mA) | 7 | 3.5 | 3.5 | 3.5 | EDL | 5 | EDL |

EDL, electrodeless discharge lamp. Flame type was air-acetylene (BOC, South Africa).
Table 2. Labeling information available with *Moringa oleifera* products sold in Zimbabwe.

| Description                             | Frequency (%) |
|-----------------------------------------|---------------|
| Formulation sold                        |               |
| Tablet                                  | 0             |
| Capsule                                 | 8             |
| Powder                                  | 92            |
| Decoction                               | 0             |
| Part plant sold                         |               |
| Bark                                    | 44            |
| Leaves                                  | 77            |
| Roots                                   | 2             |
| Unknown                                 | 8             |
| Indications                             | 71            |
| Chronic                                 | 29            |
| Acute                                   |               |
| Recommended dosage regimen              |               |
| 1 tsp daily                             | 31            |
| 1 tsp 3 × daily                         | 50            |
| 1 cap daily                             | 6             |
| 1 tsp 3 × daily                         | 19            |
| Counseling messages                     |               |
| Take with food                          | 52            |
| Take after food                         | 6             |
| Avoid when pregnant                     | 2             |
| None                                    | 40            |
| Herbal drug information references      |               |
| Traditional knowledge                   | 10            |
| Unscientific literature                 | 62            |
| Supplier                                | 46            |
| Healthcare professional                 | 0             |

Table 3. Microbial counts in *Moringa* samples.

| Test                                | Source        | Total aerobic microbial count (cfu/g) | Reference limit* | Comment   |
|-------------------------------------|---------------|--------------------------------------|-----------------|-----------|
| Total aerobic microbial count of samples | Pharmacy     | $1 \times 10^7$                      | $5 \times 10^4$ | Above limit |
|                                     | Herbal shop   | $3 \times 10^7$                      | $5 \times 10^4$ | Above limit |
|                                     | Open market   | $3 \times 10^6$                      | $5 \times 10^4$ | Above limit |
| Total fungal (yeasts and molds) count | Pharmacy     | $7 \times 10^6$                      | $5 \times 10^4$ | Above limit |
|                                     | Herbal shop   | $5 \times 10^6$                      | $5 \times 10^4$ | Above limit |
|                                     | Open market   | $4 \times 10^6$                      | $5 \times 10^4$ | Above limit |

*European Pharmacopoeia.*
Figure 1. Concentration of Ar (A), Cd (B), Ni (C), Pb (D), Cu (E), Zn (F) detected in samples.

References

1. Clauson KA, Santamarina ML, Rutledge JC. Clinically relevant safety issues associated with St. John’s worth product labels. BMC Complement Altern Med 2008;8:42.
2. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol 2013;69:295-307.
3. Lorenc A, Robinson N. A review of the use of complementary and alternative medicine and HIV: issues for patient care. AIDS Patient Care STDS 2013;27:503-10.
4. Anwar F, Ashraf M, Gilani AH. Moringa oleifera: a food plant with multiple medicinal uses. Phytother Res 2007;21:17-25.
5. Mudzviti T, Maponga CC, Khoza S et al. The impact of herbal drug use on adverse drug reaction profiles of patients on anti-retroviral therapy in Zimbabwe. AIDS Res Treat 2012;2012:434171.
6. Elmer P. AY-5 analysis of plant tissue wet digestion. In: Crop PE, ed. Operational manual: atomic absorption spectrophotometer. 1991.
7. World Health Organization. WHO National policy on traditional medicine and regulation of herbal medicines. Report of a WHO global survey. 2005. Available from: http://apps.who.int/medicinedocs/pdf/s7916e/s7916e.pdf
8. World Health Organization. Guidelines for the appropriate use of herbal medicines. Geneva: WHO Regional Publications; 1998. Available from: http://apps.who.int/medicinedocs/en/d/Jh2945e/
9. World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. World Health Organization; 2007. Available from: http://apps.who.int/medicinedocs/index/assoc/s14878e/s14878e.pdf
10. Raynor DK, Dickinson R, Knapp P et al. Buyer beware? Does the information provided with herbal products available over the counter enable safe use? BMC Med 2011;9:1-9.
11. O’Brien S, Broom A. HIV in (and out of) the clinic: biomedicine, traditional medicine and spiritual healing in Harare. Sahara J 2014:94-104.
12. World Health Organization. Guidelines for clinical study of traditional medicines in
the WHO Africa region. 2004. Available from: http://apps.who.int/medicinedocs/documents/s21350en/s21350en.pdf

13. Adu-Gyamfi A, Mahami T. Effect of drying method and irradiation on the microbiological quality of moringa leaves. Int J Nutr Food Sci 2014;3:91-6.

14. Shehu K, Maishanu AM, Salau IA. A preliminary study on microbial contamination of leafy vegetables in Sokoto Metropolis, Nigeria. Aceh Int J Sci Technol 2014;3:140-4.

15. Sauveur A, Broin M. Growing and processing Moringa leaves. Moringa and Plant Resources Network 2010:55-63.

16. Offor IF, Ehiri RC, Njoku CN. Proximate Nutritional analysis and heavy metal composition of dried Moringa Oleifera leaves from Oshiri Onicha L.G.A, Ebonyi State, Nigeria. OSR J Environ Sci Tox Food Tech 2014;8:57-62.

17. Limmatvapirat C, Limmatvapirat S, Charoenteeraboon J et al. Comparison of eleven heavy metals in Moringa Oleifera Lam. products. Indian J Pharmaceut Sci 2015;77:485-90.

18. Moringa Association of Ghana. Growing and processing moringa leaves. Accra: Moringa and Plant Resources Network; 2010.

19. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Arsenic. 2007. Available from: https://www.atsdr.cdc.gov/toxprofiles/TP.asp?id=22&tid=3.

20. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Cadmium. Atlanta: U.S. Department of Health and Human Services; 2012. Available from: http://www.atsdr.cdc.gov/ToxProfiles/TP.asp?id=48&tid=15.